

Patent Assignment Abstract f Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2

Patent #: 6264922 **Issue Dt:** 07/24/2001 **Application #:** 08948216 **Filing Dt:** 10/09/1997

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS

Assignment: 1

Reel/Frame: 010797/0486 **Recorded:** 05/05/2000 **Pages:** 15

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: NANOSYSTEMS, L.L.C. **Exec Dt:** 10/01/1998

Assignee: ELAN CORPORATION, PLC
LINCOLN HOUSE, LINCOLN PLACE
DUBLIN 2, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-8696

Assignment: 2

Reel/Frame: 010797/0501 **Recorded:** 05/05/2000 **Pages:** 17

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: ELAN CORPORATION, PLC **Exec Dt:** 10/01/1998

Assignee: ELAN PHARMA INTERNATIONAL LIMITED
WIL HOUSE, SHANNON BUSINESS PARK
SHANNON, CO. CLARE, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007-8696

Search Results as of: 02/03/2004 10:51 AM

05-23-2000

Atty. Dkt. No. 029318/0440

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

5.5.00

101364078

To the Commissioner of Patents and Trademarks: Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

Elan Corporation, PLC



2. Name and address of receiving party(ies):

Elan Pharma International Limited
WIL House, Shannon Business Park
Shannon, Co. Clare
IRELAND

Additional conveying party(ies)

3. Nature of conveyance:

ASSIGNMENT

Execution Date: October 1, 1998

Additional name(s) & address(es) attached?

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is: /

A. Patent Application Number(s):

08/948,216

B. Patent Number(s):

Additional numbers attached?

5. Name and address of party to whom correspondence concerning document should be mailed:

Michele M. Schafer
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
P.O. Box 25696
Washington, D.C. 20007-8696

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

 Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

05-23-2000 JMM/MS 00000073 00944216

DO NOT USE THIS SPACE

01 PC:581

40.00 (P)

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Michele M. Schafer

Name of person signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 17

ASSIGNMENT AGREEMENT

ASSIGNMENT AGREEMENT among Elan Corporation, plc ("Elan") and Elan Pharma International Limited, a wholly-owned subsidiary of Elan ("EPIC"), for consideration consisting of an amount in cash equal to the Purchase Price (as defined in the Agreement) less the sum of the amounts paid by EPIC pharmaceutical Research Corp. ("EPIC") to Elan in consideration for the assets separately conveyed plus the amounts paid by EPIC to Nanosystems L.L.C. for certain licensed improvements, the parties hereto agree that, effective immediately after the closing of the transactions referred to in the Agreement referred to below, Elan assigns to EPIC all of Elan's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanosurgical version of Facitaxel) in accordance with the terms of the Asset Purchase Agreement (the "Agreement") by and among Nanosystems L.L.C., Eastman Kodak Company and Elan.

Capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement.

(signature page follows)

-2-

IN WITNESS WHEREOF, the parties hereto have executed
this Assignment Agreement as of the 1st day of October, 1998.

ELAN CORPORATION, PLC

By: 
Name: Donald J. Slaney
Title: Chairman of Board
Director of Elan Corp., plc

We hereby assume the rights, title and interest specified
above.

ELAN PHARMA INTERNATIONAL
LIMITED

By: 
Name: David H. Miller
Title: Director



ASSET PURCHASE AGREEMENT

by and between

NANOSYSTEMS L.L.C.,

EASTMAN KODAK COMPANY

and

ELAN CORPORATION, PLC

Dated as of August 21, 1998

NY12528:97445.11

PATENT

REEL: 010797 FRAME: 0504



SCHEDULES TO DISCLOSURE STATEMENT

Schedule 1.1(a)	Equipment
Schedule 1.1(b)	NanoSystems Real Property
Schedule 1.1(c)	NanoSystems Intellectual Property
Schedule 3.8	Capitalization
Schedule 3.10	Absence of Change
Schedule 4.5	Consents
Schedule 4.6(a)	Intellectual Property Infringements
Schedule 4.6(b)	Intellectual Property Restrictions
Schedule 4.8(a)	Material Contracts
Schedule 4.8(b)	Contract: Breaches/Events
Schedule 4.8(c)	Certain Contracts
Schedule 4.9	Manufacturing Rights
Schedule 4.10	Administrative Actions
Schedule 4.13(a)	Benefit Plans
Schedule 4.13(f)	Payments Resulting from Transactions
Schedule 4.14(b)	Environmental
Schedule 4.17(c)	Commitments Since 12/31/97
Schedule 4.17(g)	Severance Payment
Schedule 4.20	Undisclosed Liabilities
Schedule 4.21	Insurance
Schedule 4.22	Year 2000 Compliance
Schedule 5.2	Commitments Prior to Closing
Schedule 5.5(a)	Severance Plan
Schedule 5.5(b)	Kodak Employee
Schedule 6.1(c)	Consents

EXHIBIT A Warrant Agreement

*Schedule
1.1(c)*

IP

SCHEDULE 1.1.c

MAY 05 2000

NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents

August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Aerosols Containing Dechlorinated Nanoparticulate Dispersions	U.S.	Patent No. 5,747,501	Granted
	Canada	Appn. No. 2,113,640	Pending
	Europe	Appn. No. 96004567.1	Pending
	Japan	Appn. No. 6-323793	Pending
	U.S.	Appn. No. 08/743,316	Pending
	Canada	Appn. No. 2,113,634	Pending
	Europe	Appn. No. 96004566.3	Pending
	Japan	Appn. No. 6-323791	Pending
Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surfaces Stabilizers and Methods of Making Such Formulations	U.S.	Appn. No. 08/750,402	Pending
	PCT	PCT/US98/14297	Pending
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature	U.S.	Patent No. 5,343,183	Granted
	U.S.	Patent No. 5,705,794	Granted
	Canada	Appn. No. 2,113,643	Pending
	Europe	Appn. No. 96007083.3	Pending
	Japan	Appn. No. 6-323163	Pending
Nanoparticles Comprising the R(-) Enantiomer of Isoprofin	U.S.	Patent No. 5,718,919	Granted
Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays	U.S.	Patent No. 5,343,184	Granted
Microprecipitation of Nanoparticulate Pharmaceutical Agents	U.S.	Patent No. 5,360,932	Granted
Isolation of Ultra Small Particles	U.S.	Patent No. 5,303,723	Granted
Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,643,332	Granted
	U.S.	Patent No. 5,472,683	Granted
	U.S.	Patent No. 5,373,749	Granted
Iodinated Arachoxy Esters	U.S.	Patent No. 5,322,679	Granted
	U.S.	Patent No. 5,464,413	Granted
	U.S.	Patent No. 5,318,157	Granted
Method of Urinating Pharmaceutical Substances	Argentina	Appn. No. 3214,304	Pending
	Australia	Patent No. 6220132	Granted
	Canada	Appn. No. 2,107,400	Pending
	Taiwan	Patent No. NI-69478	Granted
	Czech Republic	Appn. No. 93/2277	Pending
	Europe	Appn. No. 93202795.6	Pending
	Finland	Patent/Appn. No. 934320	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents

August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Method of Grading Pharmaceutical Substances	Hungary	Patent No. 216228	Granted
	Japan	Appn. No. 10245775	Pending
	South Korea	Appn. No. 2272453	Pending
	Malaysia	Patent No. MY-109415A	Granted
	Mexico	Appn. No. 93-0443	Pending
	New Zealand	Patent No. 241813	Granted
	Norway	Appn. No. 15-05715	Pending
	Philippines	Appn. No. 1147039	Pending
	Austria	Patent/Appn. No. 9143296	Pending
	Slovak Republic	Appn. No. PV 130175	Pending
	Ukraine	Appn. No. 93-3406	Pending
	Venezuela	Appn. No. 148445	Pending
	U.K.	Patent No. 3,373,711	Granted
Reversable Nanoparticle Film Matrices With Protective Overcoats	Canada	Appn. No. 2,212,800	Pending
	Europe	Appn. No. 9493412.7	Pending
	Japan	Appn. No. 6-223046	Pending
	U.S.	Patent No. 5,384,107	Granted
	U.S.	Patent No. 5,384,101	Granted
Indicated Aromatic Compounds	U.S.	Patent No. 5,330,738	Granted
Method to Reduce Particle Size Growth During Lyophilization	U.S.	Patent No. 5,371,336	Granted
Indicated Benzoyl Acetals and Ketals for X-Ray Imaging	U.S.	Patent No. 5,363,131	Granted
Formulations of Compounds as Nanoparticle Dispersions in Digestible Oils or Fatty Acids	Canada	Appn. No. 2,207,304	Pending
	Europe	Appn. No. 9493413.3	Pending
	Japan	National Phase Appn. of PCT/US96/01633	Pending
Use of Non-ionic Cloud Point Modifiers to Minimize Nanoparticle Aggregation During Sterilization	U.S.	Patent No. 5,345,762	Granted
The Use of Tylexupel as a Nanoparticle Stabilizer and Dispersant	U.S.	Patent No. 5,429,324	Granted
	Argentina	Appn. No. 326,179	Pending
	Australia	Patent No. 685648	Granted
	Canada	Appn. No. 2,164,192	Pending
	Taiwan	Appn. No. 02105700	Pending
	Europe	Appn. No. 9283343.7	Pending
	Finland	Pat/Appn. No. 93/1005	Pending
	Hungary	Pat/Appn. No. 93/11524	Pending
	Israel	Appn. No. 93/10774	Pending
	Japan	Appn. No. 200790463	Pending
	South Korea	Appn. No. 22700930	Pending

SCHEDULE 1.J.2

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
The Use of Tylacopal as a Nanoparticle Stabilizer and Dispersant	Malaysia	Appn. No. PI 9302336	Granted
	New Zealand	Patent No. 248728	Granted
	Norway	Appn. No. P934424	Pending
	Philippines	Patent No. 25937	Granted
	Russia	Appn. No. 93034941.00	Pending
	Slovak Republic	Appn. No. PV 1434-93	Pending
	Ukraine	Appn. No. 11001742	Pending
	U.S.	Patent No. 5,361,478	Granted
Luminated Aryloxy Carbonamides	Argentina	Appn. No. 126,629	Pending
	Australia	Patent No. 443442	Granted
	Canada	Appn. No. 2,167,397	Pending
	Taiwan	Patent No. TI-072,917	Granted
	Hungary	Pat/Appn. No. P9301475	Hungary
	Israel	Appn. No. 93/107,634	Granted
	Japan	Appn. No. 210915291	Pending
	South Korea	Appn. No. 93/211134	Pending
	Malaysia	Patent No. MY-182,103A	Granted
	New Zealand	Patent No. 248431	Granted
	Philippines	Patent No. J0136	Granted
	Ukraine	Appn. No. 110,3409	Pending
	Venezuela	Patent No. 135,453	Granted
X-Ray Contrast Compositions Useful in Medical Imaging	U.S.	Patent No. 5,431,393	Granted
	U.S.	Patent No. 5,318,767	Granted
	Europe	Appn. No. 92200132.4	Pending
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	U.S.	Patent No. 5,352,459	Granted
	Argentina	Appn. No. 116,525	Pending
	Taiwan	Appn. No. 83109723	Pending
	Japan	Appn. No. 21647283	Pending
	South Korea	Appn. No. 93/211135	Pending
	Malaysia	Appn. No. P193021359	Pending
	Mexico	Appn. No. 937181	Pending
	New Zealand	Patent No. 230,116	Granted
	Philippines	Appn. No. 47231	Pending
	Austria	Appn. No. 93/31815	Pending
	Slovak Republic	Appn. No. PV 1416/93	Pending
Formulations of Nanoparticulate Naproxen Tablets	U.S.	Appn. No. 08/100,006	Pending
	PCT	PCT/US93/03188	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998			
Title of Invention	Country	Patent/Appn. No.	Status
Reduction of Intravenously Administered Nanoparticle Formulations Induced Adverse Physiological Reactions	U.S.	Appn. No. 08/494,754	Pending (Allowed)
	Canada	Based on PCT/US96/15300	Pending
	Europe	Based on PCT/US96/15300	Pending
	Japan	Based on PCT/US96/15300	Pending
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles Having Cross-Linkable Block Copolymer Surface as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,343,113	Granted
	U.S.	1,367,143	Granted
	Argentina	Appn. No. 132,213	Pending
	Australia	Appn. No. 2,634,093	Pending
	Canada	Appn. No. 2,151,503	Pending
	Taiwan	Appn. No. 0405107331	Pending
	Europe	Appn. No. 9392138000	Pending
	Finland	Pat./Appn. No. 943214	Pending
	Israel	Patent/Appn. No. 93/14334	Pending
	Japan	Appn. No. 501303794	Pending
	Malaysia	Appn. No. 911301774	Pending
	Norway	Appn. No. 7 943,433	Pending
	Philippines	Appn. No. 16800	Pending
	Venezuela	Appn. No. 93/1026	Pending
Method of Grinding Pharmaceutical Substances	U.S.	Appn. No. 08/491,339	Pending (Allowed)
	Argentina	Appn. No. 231,533	Pending
	Canada	Appn. No. 2,150,565	Pending
	Taiwan	Appn. No. 04104440	Pending
	Europe	Appn. No. 939138204	Pending
	Israel	Appn. No. 93/13062	Allowed
	Japan	Appn. No. 5343245	Pending
	Malaysia	Appn. No. 911301374	Pending
	Philippines	Appn. No. 50373	Pending
	Venezuela	Appn. No. 0153-35	Pending
Nanoparticle Diagnostic Dimmers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,360,204	Granted
Method of Preparing Stable Drug Nanoparticles	U.S.	Patent No. 5,334,570	Granted
Sulfated Non-Ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,369,448	Granted
Iodinated Aromatic Propenocarbonates	U.S.	Patent No. 5,254,610	Granted
	U.S.	Patent No. 5,328,404	Granted
Iodinated Aromatic Ketones	U.S.	Patent No. 5,418,113	Granted

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Novel Purpose Diagnostic/Therapeutic Agents Having a Tri-Indicated Benzylic Group Attached to a Carboxide	U.S.	Patent No. 5,645,330	Granted
Novel Formulations of Oral Subintestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Patent No. 5,621,981	Granted
Novel Formulations of Oral Subintestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Appn. No. 08/813,348	Pending
Novel Formulations of Iodopanide Derivatives for Oral X-Ray Contrast Agents	U.S.	Patent No. 5,525,318	Granted
Novel Particulate Diagnostic/Therapeutic Enteric X-Ray Contrast Agents for Blood Pool and Hepatic System Imaging	U.S.	Patent No. 5,525,328	Granted
Novel Salt Formulations Stabilized by Non-Ionic and Anionic Stabilizers	U.S.	Patent No. 5,383,437	Granted
Novel Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents	U.S.	Patent No. 5,401,452	Granted
Novel Formulations for Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-Ionic surfactants	U.S.	Patent No. 5,356,357	Granted
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Crystallization	U.S.	Patent No. 5,447,716	Granted
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Crystallization	U.S.	Patent No. 5,498,262	Granted
Use of Charged Phospholipids to Reduce Particle Aggregation	U.S.	Patent No. 5,470,373	Granted
Process of Preparing Therapeutic Compositions Containing Nanoparticles	U.S.	Patent No. 5,310,318	Granted
Nanoparticulate NSAID Formulations	U.S.	Patent No. 5,318,738	Granted
Nanoparticulate NSAID Formulations	Canada	Appn. No. 2,112,779	Pending
Nanoparticulate NSAID Formulations	Europe	Appn. No. 90025181.2 (to be completed in all EP designated countries)	Pending (Allowed)
Nanoparticulate NSAID Formulations	Japan	Appn. No. 5-324241	Pending
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents	U.S.	Patent No. 5,360,932	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents Using Surface Active Material Derived From Similar Pharmaceutical Agents	U.S.	Patent No. 5,716,642	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,645,331	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,642,153	Granted
Surfactant Modified Drug Nanoparticles	U.S.	Patent No. 5,145,584	Granted
Surfactant Modified Drug Nanoparticles	Argentina	Appn. No. 92/321681	Pending

SCHEDULE 1.1.e

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Drug Nanoparticles	Australia	Patent No. 634136	Granted
	Canada	Appn. No. 2559433	Pending
	Chile	Appn. No. 22674	Pending
	Colombia	Patent No. 24413	Granted
	Europe	Appn. No. 92251513 Publication No. 491039	Pending
	Finland	Pat/Appn. No. 510021	Pending
	Hungary	Pat/Appn. No. 10-224	Pending
	Ireland	Appn. No. 12-0117	Pending
	Israel	Patent/Appn. No. 166754	Granted
	Japan	Appn. No. 51/1224	Pending
	South Korea	Appn. No. 51/1077	Pending
	Malaysia	Patent No. MY-160134-A	Granted
	Mexico	Patent No. 176143	Granted
	New Zealand	Patent No. 241142	Granted
	Norway	Appn. No. 52-00134	Granted
	Philippines	Patent No. 25639	Granted
	Russia	Pat. No. 2024300	Granted
	Singapore	Appn. No. 5504351-J	Pending
	Taiwan	Patent No. NJ-071112	Granted
	U.K.	Patent No. 5,394,643	Granted
	U.S.	Patent No. 5,195,343	Granted
	Argentina	Appn. No. PV/111120	Pending
	Australia	Patent No. 675433	Granted
	Canada	Appn. No. 2559432	Pending
	Czech Republic	Appn. No. PV 131673	Pending
	China	Appn. No. 93100150.9	Pending
	Europe	Appn. No. 93201883.1 Publication No. 577215	Pending
	Finland	Pat/Appn. No. 511040	Pending
	Hungary	Pat/Appn. No. 19101917	Pending
	Israel	Patent/Appn. No. 166138	Pending
	Japan	Appn. No. 51/135368	Pending
	South Korea	Appn. No. 51/11247	Pending
	Malaysia	Appn. No. 51/0301273	Pending (Allowed)
	Mexico	Appn. No. 511950	Pending
	New Zealand	Patent No. 241142	Granted
	Norway	Appn. No. 52-00133	Pending
	Philippines	Patent No. 25634	Granted
	Russia	Appn. No. 5504356	Pending
	Singapore	Appn. No. 5505005-6	Pending
	Slovak Republic	Pat/Appn. No. PV 0681-73	Pending
	Taiwan	Patent No. NJ-075124	Granted
	Ukraine	Appn. No. 55001357	Pending

SEARCHING AND GRANTED PATENTS
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Anticancer Nanoparticles	Yuanzhi	Pat/Appn. No. 0345-93	Pending
Surface Modified NIAID Nanoparticles	U.K.	Patent No. 3352,160	Granted
	Australia	Patent No. 677713	Granted
	Austria	Europes Patent No. 644 755	National Registration of EP 644 755
	Belgium	European Patent No. 644 755	National Registration of EP 644 755
	Canada	Appn. No. 2118317	Pending
	Denmark	European Patent No. 644 755	National Registration of EP 644 755
	Europe	European Patent No. 644 755	Granted
	France	European Patent No. 644 755	National Registration of EP 644 755
	Germany	European Patent No. 644 755	National Registration of EP 644 755
	Greece	European Patent No. 644 755	National Registration of EP 644 755
	Hungary	Pat/Appn. No. 34.3343	Pending
	Ireland	European Patent No. 644 755	Granted
		Irish Patent No. 172603	
	Italy	European Patent No. 644 755	National Registration of EP 644 755
	Japan	Appn. No. 94/301313	Pending
	Luxembourg	European Patent No. 644 755	National Registration of EP 644 755
	Morocco	European Patent No. 644 755	National Registration of EP 644 755
	Mexico	Appn. No. 93-3432	Pending
	Netherlands	European Patent No. 644 755	National Registration of EP 644 755
	Portugal	European Patent No. 644 755	National Registration of EP 644 755
	Spain	European Patent No. 644 755	National Registration of EP 644 755

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Modified NSAID Nanoparticles	Sweden	European Patent No. 644 733	National Registration of EP 644 733
	Switzerland	European Patent No. 644 733	Granted
	United Kingdom	European Patent No. 644 733	National Registration of EP 644 733
Use of the Adsorption Within the GI-Tract Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene Oxide) Polymers	U.S.	Patent No. 5,563,379	Granted
Use of Imaging X-Ray Contrast Agents Based on Encapsulated Surfactant for Nanocrystals	U.S.	Patent No. 5,571,730	Granted
Applications of Oral Gastrointestinal Nanocrystals as X-Ray Contrast Agents in Combination with Pharmaceuticals and with Pharmaceutically Acceptable Clays	U.S.	Patent No. 5,522,618	Granted
Use of Naproxen with Hydroxypropyl Methyl Cellulose as a Dispersion Stabilizer	U.S.	Patent No. 5,466,440	Granted
2-(Aminooxy)-3,5-Dimethyl-3-Substituted-Amino-5-Ethoxy Esters Useful as X-Ray Contrast Agents for Medical Diagnostic Imaging	U.S.	Patent No. 5,391,436	Granted
2-(Aminooxy)-3,5-Dimethyl-3-Ethoxy Esters	U.S.	Patent No. 5,370,134	Granted
Improved Method of Grinding Pharmaceutical Substances	U.S.	Patent No. 5,363,918	Granted
Novel X-Ray Contrast Agents	Argentina	Appn. No. 331,837	Pending
	Canada	Appn. No. 2,190,134	Pending
	Taiwan	Appn. No. 84101342	Pending
	Europe	Appn. No. 93910582.0	Pending
	Israel	Appn. No. 173051	Pending
	Japan	Appn. No. 53/236017	Pending
	Malaysia	Appn. No. 711501375	Pending
	Philippines	Appn. No. 93/50374	Pending
	Venezuela	Appn. No. 0134-93	Pending
	U.S.	Appn. No. 08/677,768	Pending
Novel Trialkylphenyl Esters as Novel X-Ray Contrast Agents	U.S.	Patent No. 5,644,186	Granted September 16, 1997
	U.S.	Appn. No. 08/134,119	Pending
	Argentina	Appn. No. 331,135	Pending
	Canada	Appn. No. 2,187,388	Pending
	Taiwan	Appn. No. 8400102792	Pending
	Europe	Appn. No. 939043204	Pending
	Israel	Appn. No. 94/0112136	Pending
	U.S.	Appn. No. 08/134,119	Pending
	U.S.	Appn. No. 08/134,119	Pending
	U.S.	Appn. No. 08/134,119	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 26, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Other Copolymers and a Process for Making Them	Europe	National Phase of PCT/EP94/04281	Pending
	Japan	National Phase of PCT/JP94/04261	Pending
	Malaysia	Appn. No. 919500032	Pending
	Mexico	Appn. No. 931133	Pending
	Philippines	Appn. No. 930136	Pending
	Greece	Patent No. 2141577	Granted
	British		
	Venezuela	Appn. No. 930114	Pending
Octahedral Crystalline Form of Triamcinolone Acetonide, Compositions Involving the Rhomboctahedral Crystalline Form of Triamcinolone Acetonide, Methods of Making and Using Such Compositions, Methods of Making Nanocrystalline Compositions of Tetragonal Crystalline Form of Triamcinolone Acetonide and Stable Formulations of Naproxen	U.S.	Appn. No. 08/943,281	Pending
		Appn. No. Unknown (filed on August 13, 1998)	Pending

the Acquired Assets are subject, other than in the case of clauses (ii) and (iii) any conflict, breach, default, termination, cancellation, acceleration, loss, violation or Encumbrance which, individually or in the aggregate, would not have a Material Adverse Effect or materially impair or delay Seller's ability to perform its obligations hereunder.

4.4 Binding Effect. This Agreement constitutes a valid and legally binding obligation of Seller enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles.

4.5 Consents and Approvals. Except as required by the H-S-B Act, no consent, approval, waiver or authorization is required to be obtained by Seller from, and no notice or filing is required to be given by Seller to or made by Seller with, any Federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Seller of this Agreement other than those the failure of which to obtain, give or make would not have a Material Adverse Effect or materially impair or delay the ability of Seller to effect the Closing.

4.6 Intellectual Property. To the best Knowledge of Seller, Seller owns or has the right to use all of the Intellectual Property included in the Acquired Assets. The Intellectual Property included in the Acquired Assets constitutes all of the Intellectual Property necessary to conduct the Business as currently conducted. Schedule 1.1(c) contains a worldwide list of all patents, trade names, trademarks and service marks, and applications for the foregoing owned or possessed by the Seller and true and complete copies of all such materials have been made available to Buyer. Seller has taken all action reasonably necessary to establish and protect its interest in and to the NanoSystems Intellectual Property. To the Knowledge of Seller, (i) Seller's products do not infringe on or otherwise violate the Intellectual Property of any other Person, and (ii) no Person is challenging, infringing or otherwise violating the NanoSystems Intellectual Property. Except as set forth in the Contracts listed on Schedule 4.6(b), there is no limitation on Seller's ability or right to license any of the NanoSystems Intellectual

Property to any Person. All issued patents and registered trademarks and service marks owned by Seller are recorded on the public record solely in the name of Seller.

4.7 Title to and Condition of Tangible Property. Seller has good title to, or a valid and binding leasehold interest in, the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except (i) Liens for Taxes, Assessments and other governmental charges (a) not yet due and payable or (b) being contested in good faith by appropriate proceedings and for which adequate reserves have been established, and (ii) Encumbrances which, individually or in the aggregate, would not have a Material Adverse Effect. Upon the consummation of the transactions contemplated hereby, assuming Buyer is a bona fide purchaser for value with no knowledge of an adverse claim, Buyer will acquire good title to the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except for the exceptions in clauses (i) and (ii) of this Section 4.7. The tangible property included in the Acquired Assets is in all material respects in good working condition, ordinary wear and tear excepted.

4.8 Contracts.

(a) Schedule 4.8(a) sets forth a list, as of the date hereof, of each Contract that is material to Seller. Each such Contract is a valid and binding agreement of Seller or its Affiliates and is in full force and effect.

(b) To the Knowledge of Seller, there has been no material breach or default under any Contract listed on Schedule 4.8(a) except for defaults that have been cured or waived and breaches and defaults which are not material. No event has occurred with respect to Seller which, with notice or lapse of time or both, would constitute a material breach, violation or default, or give rise to a right of termination, cancellation, foreclosure, imposition of a lien or penalty, prepayment or acceleration under any such Contract.

(c) Seller is not a party to any Contract in any of the following categories:

NY12528:97443 11

-18-


ASSIGNMENT OF INTELLECTUAL PROPERTY OTHER THAN PATENTS

KNOW ALL PERSONS BY THESE PRESENTS that in connection with the Asset Purchase Agreement, dated as of August 21, 1998 (the "Agreement"), by and among Elan Corporation, plc, a public limited company organized under the laws of Ireland ("Buyer"), NanoSystems L.L.C., a limited liability company organized under the laws of the State of Delaware ("Seller"), and Eastman Kodak Company, a New Jersey corporation (capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement), Seller, for good and valuable consideration, receipt of which is hereby acknowledged, hereby **ASSIGNS** to Buyer all of Seller's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanoparticle version of Paclitaxel) in accordance with the terms of the Agreement.

IN WITNESS WHEREOF, Seller has caused this instrument to be executed by its duly authorized officer on the 1st day of October, 1998.

NANOSYSTEMS L.L.C.

By: Particulate Prospects Corp.,
Member

By: 
Name: Akram Sandhu
Title: Vice President

NY12524 19981203

RECORDED: 05/06/2000

Fron-

Received 04-22-00 11:06 am

To: FOLEY AND LARDNER Page 05
PATENT
REEL: 010797 FRAME: 0517